Completed
Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
NCT04064242
- Conditions
- Hemic and Lymphatic Diseases, Hypersensitivity, Hypersensitivity, Delayed, +9 more
- Locations
-
- Novartis Investigative Site Birmingham, Alabama, United States
- Univ of Florida College of Medicine x Gainesville, Florida, United States
- University of Kansas Medical Center Kansas City, Kansas, United States
- John Hopkins Asthma And Alrgy Cntr Baltimore, Maryland, United States